ClinicalTrials.gg
RecruitingNCT06824064VISTA-1Updated Nov 5, 2026

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

A Phase 2 interventional study of RBS2418 and Placebo in Metastatic Colorectal Cancer and Advanced Colorectal Cancer, sponsored by Riboscience, LLC.. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Riboscience, LLC. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 5, 20264 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,341 studies in Colorectal Neoplasms with a site in United States — 417 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
621st of 1,933
150 · median 64
Started
2025
with 143 others
Phase 2
511 of 2,341
66 open now
Primary completion
2027-12
later than 353 of 627 live
Registered
2,120th of 2,341
by date

Among the 2,341 studies in Colorectal Neoplasms with a site in United States, this one is the 621st largest by planned enrollment of the 1,933 interventional ones that give a count, is one of 144 that started in 2025, is one of 511 in phase 2, reaches primary completion later than 353 of the 627 other live ones, and was the 2,120th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

417 of the 2,341 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 417 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,341 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).

Read the detailed description

In this Phase 2a study, subjects must have failed, been unable to tolerate, or declined to take known standard-of-care (SOC) therapies. Subjects must have measurable disease per RECIST 1.1, an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2, and predicted life expectancy of greater or equal to 3 months.

Up to approximately 150 subjects will be enrolled and will receive therapy as part of their respective treatment group. Subjects will receive study treatment of RBS2418 or Placebo to Match plus Best Supportive Care with a treatment period consisting of 21-day cycles up to two years or until there is progressive disease (PD), death, withdrawal, or study completion, whichever comes first.

Adverse events (AEs) will be monitored throughout the study and graded in severity according to the guidelines outlined in the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. AEs will be collected until up to 30 days after the end of treatment or until resolution, whichever comes first. Serious Adverse Events (SAEs) will be collected for 90 days after the end of treatment, or if the subject initiates new anti-cancer therapy, then 30 days after the end of treatment, whichever is earlier.

03

Conditions studied

  • Metastatic Colorectal Cancer
  • Advanced Colorectal Cancer

Keywords

  • Advanced, Metastatic, Progressive Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age on the day of signing .
  2. Male and female subjects with advanced, , progressive CRC who have received, been ineligible for, intolerant to, or declined all approved standard of care (SOC) therapies for metastatic CRC, as per local SOC treatment regimens. Additionally, subjects must have documented PD based on two scans performed within 2 to 4 months of study initiation.
  3. Have or cytologically confirmed CRC diagnosis based on pathology report.
  4. Willing to submit a pre-treatment tissue sample (archival, or fresh tissue if archival is not available).

Exclusion criteria

Exclusion Criteria:

  1. Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy within 2 weeks prior to the first dose of study treatment; or if subject has not recovered (i.e., ≤ to Grade 1 or returned to baseline level) from AEs due to a previously administered agent; the following exceptions are allowed:

    • Palliative radiotherapy for bone or soft tissue lesions should be completed >7 days prior to the first dose of study treatment.
    • Hormone-replacement therapy or oral .
    • Subjects with Grade 2 neuropathy or Grade 2 alopecia.
  2. Subjects with evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.
  3. other than indications open for enrollment within 3 years prior to Day 1, except for those with negligible risk of metastasis or death treated with expected curative outcome, undergoing active surveillance, or treatment-naïve for indolent tumors.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Group A: EG+ [ENPP1 and cGAS(Cyclic GMP-AMP synthase) positive] RBS2418 plus Best Supportive Care

    RBS2418: 200 mg (2 RBS2418 capsules), PO (by mouth), BID (twice a day) plus Best Supportive Care

    Drug: RBS2418

  • Placebo comparator
    Group B: EG+ (ENPP1 and cGAS positive) Placebo plus Best Supportive Care

    Placebo: 2 placebo capsules, PO, BID plus Best Supportive Care

    Drug: Placebo

  • Active comparator
    Group C: EG- (ENPP1 and/or cGAS negative) RBS2418 plus Best Supportive Care

    RBS2418: 200 mg (2 RBS2418 capsules), PO, BID plus Best Supportive Care

    Drug: RBS2418

  • Placebo comparator
    Group D: EG- (ENPP1 and/or cGAS negative) Placebo plus Best Supportive Care

    Placebo: 2 placebo capsules, PO, BID plus Best Supportive Care

    Drug: Placebo

Interventions

  • RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.

  • DrugPlacebo

    Placebo to Match RBS2418

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Time in months from randomization until the first radiographic documentation of objective progression, as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or death from any cause

    Time frame: From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.

  2. Overall Survival

    Time in months from the date of randomization to the date of death from any cause

    Time frame: From randomization until death from any cause, assessed up to 2 years.

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the time in months from initial response \[when complete response (CR) or partial response (PR) is first determined\] to disease progression or death, whichever comes first.

    Time frame: From initial response to disease progression or death, assessed up to 2 years.

  2. Disease Control Rate (DCR)

    DCR is defined as the percentage of subjects who achieve a complete response (CR), a partial response (PR) or stable disease (SD).

    Time frame: From randomization to end of treatment or disease progression, assessed up to 2 years.

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 35 months is close to that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2025
First posted
Feb 13, 2025
StartActual
Jan 17, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed
Show 4 added (2 United States, 2 Vietnam)
  • Comprehensive Cancer Centers of Nevada · Las Vegas, United States
  • SCRI Oncology LLC · Nashville, United States
  • Tam Anh, Ha Noi General Hospital · Hanoi, Vietnam
  • Oncology Hospital · Ho Chi Minh City, Vietnam
Show 1 removed
  • Tam Anh, Ha Noi General Hospital · Hà Nội, Vietnam
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    4 sites added, 1 site removed
    Show 4 added (2 United States, 2 Vietnam)
    • Comprehensive Cancer Centers of Nevada · Las Vegas, United States
    • SCRI Oncology LLC · Nashville, United States
    • Tam Anh, Ha Noi General Hospital · Hanoi, Vietnam
    • Oncology Hospital · Ho Chi Minh City, Vietnam
    Show 1 removed
    • Tam Anh, Ha Noi General Hospital · Hà Nội, Vietnam
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06824064
Lead sponsor
Riboscience, LLC.
Collaborators
Tam Anh Research Institute
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Jan 17, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Riboscience Clinical Trials
Contact
clinicaltrials@riboscience.com
(415) 754-3182

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENPP1 Inhibitor RBS2418

Start the discussion